Genetic Targets, Financial Creativity: BridgeBio's Model for Sustainable Drug Development

Biotech drug development is a high-risk, capital-intensive endeavor, requiring a balance between scientific advancement and financial reward. In this case study, we present BridgeBio's portfolio-based operating model, which integrates genetically validated targets with operational discipline and innovative financial structuring to enable rapid and scalable development. We situate BridgeBio's approach within the broader landscape of biotech operating archetypes and contrast it with more traditional approaches (e.g., single-asset, platform-based, venture-creation) models. This case study contributes to ongoing discussions about how portfolio-based strategies can improve the resilience and efficiency of biopharmaceutical innovation.